Acorda Therapeutics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Acorda Therapeutics stock.
View analyst ratings for Acorda Therapeutics or view top-rated stocks.

Wall Street analysts have given Acorda Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acorda Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Acorda Therapeutics.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($2.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($3.71) by $1.25. The biopharmaceutical company had revenue of $28.86 million for the quarter, compared to analysts' expectations of $22.15 million. Acorda Therapeutics had a net margin of 25.71% and a trailing twelve-month return on equity of 15.07%.
View Acorda Therapeutics' earnings history.

Acorda Therapeutics' stock was trading at $6.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACOR stock has decreased by 38.4% and is now trading at $3.73.
View which stocks have been most impacted by COVID-19.

Acorda Therapeutics shares reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of Acorda Therapeutics stock prior to the reverse split would have 17 shares after the split.

2 Wall Street analysts have issued 12 month price objectives for Acorda Therapeutics' shares. Their forecasts range from $6.00 to $35.00. On average, they anticipate Acorda Therapeutics' stock price to reach $17.00 in the next year. This suggests a possible upside of 355.8% from the stock's current price.
View analysts' price targets for Acorda Therapeutics or view top-rated stocks among Wall Street analysts.

39 employees have rated Acorda Therapeutics CEO Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among Acorda Therapeutics' employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Novavax (NVAX), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of ACOR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Acorda Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include United Asset Strategies Inc. (0.29%). Company insiders that own Acorda Therapeutics stock include Jane Wasman and Ron Cohen.
View institutional ownership trends for Acorda Therapeutics.

ACOR stock was purchased by a variety of institutional investors in the last quarter, including United Asset Strategies Inc..
View insider buying and selling activity for Acorda Therapeutics or or view top insider-buying stocks.

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACOR stock can currently be purchased for approximately $3.73.

Acorda Therapeutics has a market capitalization of $35.39 million and generates $152.97 million in revenue each year. The biopharmaceutical company earns $-99,590,000.00 in net income (profit) each year or ($12.32) on an earnings per share basis.

Acorda Therapeutics employs 167 workers across the globe.

Acorda Therapeutics was founded in 1995.

The official website for Acorda Therapeutics is www.acorda.com.

Acorda Therapeutics is headquartered at 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at (914) 347-4300.